3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 4
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Urologic Neoplasms
1
Neoplasms
1
Myasthenia Gravis
1
Melanoma
1
Limbic Encephalitis
1
Hematologic Neoplasms
1
Epilepsy
1
Epilepsies, Partial
1
Drug Resistant Epilepsy
1
Colonic Neoplasms
1
Autoimmune Diseases of the Nervous System
1
Autoimmune Diseases
1
Interventions
efgartigimod alfa
2
Rituximab
2
Hizentra
2
zilucoplan
1
thymoglobulin
1
rozanolixizumab
1
rhoA GTP-Binding Protein
1
prednylidene
1
iscalimab
1
inebilizumab
1
gamma-Globulins
1
eculizumab
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
apraclonidine
1
Sternotomy
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Methotrexate
1
Melphalan
1
Immunoglobulins, Intravenous
1
HBM9161
1
Fluid Therapy
1
Etoposide
1
Cytarabine
1
Carmustine
1
CK-2017357
1
Bortezomib
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Myasthenia Gravis
×
Immunoglobulins, Intravenous
×
Clear all
NCT04728425
2025-04-27
MG_SCIG
University Health Network, Toronto
Phase 2
Completed
30 enrolled